Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
QNCX 
Quince Therapeutics, Inc. (QNCX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: QNCX (4-star) is a SELL. SELL since 2 days. Simulated Profits (25.23%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.67
1 Year Target Price $7.67
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 94.61% | Avg. Invested days 35 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 149.23M USD | Price to earnings Ratio - | 1Y Target Price 7.67 |
Price to earnings Ratio - | 1Y Target Price 7.67 | ||
Volume (30-day avg) 4 | Beta 1.16 | 52 Weeks Range 0.72 - 4.55 | Updated Date 01/9/2026 |
52 Weeks Range 0.72 - 4.55 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.1% | Return on Equity (TTM) -247.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 140931393 | Price to Sales(TTM) - |
Enterprise Value 140931393 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.44 | Shares Outstanding 55681490 | Shares Floating 46497942 |
Shares Outstanding 55681490 | Shares Floating 46497942 | ||
Percent Insiders 9.33 | Percent Institutions 24.81 |
Upturn AI SWOT
Quince Therapeutics, Inc.
Company Overview
History and Background
Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare and orphan diseases. Founded in 2019, the company has rapidly advanced its pipeline through strategic acquisitions and internal development. Key milestones include the acquisition of promising drug candidates and the initiation of clinical trials.
Core Business Areas
- Rare Disease Therapeutics: Quince Therapeutics focuses on identifying and developing small molecule therapies for a range of rare diseases. Their pipeline targets areas with significant unmet medical needs.
- Oncology: The company is also exploring opportunities within oncology, with a particular focus on rare cancers and indications with limited treatment options.
Leadership and Structure
Quince Therapeutics is led by a team of experienced professionals in drug development, clinical research, and business operations. The organizational structure is designed for agility and efficient progression of its therapeutic candidates through the development lifecycle.
Top Products and Market Share
Key Offerings
- Product Name 1: QNC-100 (Description: A novel small molecule inhibitor for a specific rare metabolic disorder. Market Share: Not yet applicable as it is in clinical development. Competitors: Dependent on the specific indication, but generally other rare disease focused biotechs.
- Product Name 2: QNC-201 (Description: An investigational therapy for a rare oncological indication. Market Share: Not yet applicable as it is in clinical development. Competitors: Companies developing targeted therapies for rare cancers.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the rare disease sector, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. However, it also offers substantial market potential due to limited competition and premium pricing for successful therapies.
Positioning
Quince Therapeutics positions itself as a nimble and focused player in the rare disease space, leveraging strategic acquisitions to build a diversified pipeline of promising drug candidates. Its competitive advantage lies in its ability to identify and advance novel therapies for underserved patient populations.
Total Addressable Market (TAM)
The TAM for rare disease therapeutics is substantial and growing, driven by increased understanding of genetics and a greater focus on personalized medicine. Quince Therapeutics is positioned to capture a share of this TAM by addressing specific unmet needs within its chosen therapeutic areas.
Upturn SWOT Analysis
Strengths
- Focused pipeline on rare and orphan diseases
- Experienced management team
- Strategic approach to pipeline development through acquisitions
Weaknesses
- Clinical-stage company with no approved products
- Reliance on external funding
- Limited historical financial performance
Opportunities
- Significant unmet medical needs in rare diseases
- Potential for expedited regulatory pathways for rare disease drugs
- Growing market for targeted therapies
Threats
- Clinical trial failures
- Regulatory delays or rejections
- Competition from larger pharmaceutical companies
- Funding challenges
Competitors and Market Share
Key Competitors
- Alexion Pharmaceuticals, Inc. (ALXN)
- BioMarin Pharmaceutical Inc. (BMRN)
- Vertex Pharmaceuticals Incorporated (VRTX)
Competitive Landscape
Quince Therapeutics operates in a competitive landscape dominated by larger, more established biopharmaceutical companies with extensive resources and existing product portfolios. Its advantages lie in its specialization in niche rare diseases and its agile development approach, while disadvantages include limited resources and the inherent risks of drug development.
Growth Trajectory and Initiatives
Historical Growth: Quince Therapeutics has experienced rapid growth in its pipeline and organizational structure since its inception, driven by strategic acquisitions and in-licensing of promising drug candidates.
Future Projections: Future growth projections are contingent on the successful progression of its drug candidates through clinical trials and eventual market approval. Analyst estimates would focus on potential peak sales for its lead programs.
Recent Initiatives: Recent initiatives include advancing its lead drug candidates into clinical trials, expanding its research team, and potentially seeking strategic partnerships to further its development efforts.
Summary
Quince Therapeutics, Inc. is a promising clinical-stage biopharmaceutical company focused on rare diseases. Its strengths lie in its specialized pipeline and experienced team, but it faces significant risks common to early-stage biotech, including clinical trial failures and funding challenges. Success hinges on its ability to navigate the complex drug development process and achieve market approvals for its novel therapies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quince Therapeutics, Inc.
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-09 | CEO, Chief Medical Officer & Director Dr. Dirk Thye M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.quincetx.com |
Full time employees 36 | Website https://www.quincetx.com | ||
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.